Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
All articles — 31945 total
Sphere Entertainment Co. heads into September with a sharp disconnect between a stock down 17% on the week and an options market that has rarely been more bullish. The options angle is the standout this week. The…
DraftKings enters September with a sharp week-on-week decline, a fresh high-conviction initiation from a bellwether firm, and a borrow market so loose it barely registers — a combination that makes the stock's…
Vertiv Holdings enters September having defied its peer group over the past week — but the short interest story running beneath the surface is more complex than the flat weekly price move suggests. The standout tension…
SSW enters September having delivered a remarkable 32% gain over the past month — but the last week has given back nearly 5%, and the question now is whether the pullback is a pause or something more. The week's most…
BUG, the Global X Cybersecurity ETF, heads into September carrying a sharp contradiction: the fund fell 5% on Tuesday alone, yet short sellers spent the past month aggressively exiting their positions — a setup where…
Revolution Medicines enters September with the analyst re-rating from last week holding firm — and the short position that greeted those upgrades continuing to shrink, even as the stock has given back a fraction of its…
Datadog enters September having absorbed a brutal August — down 17% on its August 6 earnings day — with bears now meaningfully less aggressive than they were a month ago, yet the stock unable to recover lost…
GFL Environmental heads into September with shorts quietly retreating and the borrow market sitting comfortably loose — a setup that contrasts with the stock's flat-to-slightly-negative year so far. The positioning…
Blackstone closed the week at $136.66 — down 4.7% — while sell-side analysts were busy lifting their price targets, creating an unusual divergence between Street conviction and near-term price action. The analyst angle…
Dynatrace enters September with an unusual combination of signals: a stock up 19% in a month, shorts cutting positions sharply, options traders near their most bullish in a year, and a fresh activist filing on the…
BridgeBio Pharma enters September with the options panic from last week fully unwound, yet the underlying short position is quietly growing again — a tension worth watching as the stock slides toward its next earnings…
Personalis enters September with an unusual split personality: the stock is up 35% in a month while its close peers are getting hit hard, shorts are quietly exiting, and options traders have turned about as bullish as…
Red Cat Holdings enters September with one of the most extreme short-side setups in small-cap defense — 26% of the float shorted, zero shares left to borrow, and a Street that just split sharply on how to value it. The…
CrowdStrike has pulled back sharply from its post-earnings peak, giving up 7% on September 1 to close at $215.07 — a week that started with euphoria and ended with sellers reasserting themselves, even as the stock…
UBER enters September having given back most of last week's rebound — down 6.4% to $75.24 — yet the options market is telling a surprisingly constructive story about where investors think it goes from here. The most…
Dell Technologies has handed analysts a strong earnings beat and the market a 7% sell-off — a divergence that defines this week's setup. The post-earnings analyst response was swift and uniformly constructive. Ten…
TOST enters September with a fresh analyst downgrade, a stock down 8.7% on the week, and options traders leaning bullish — a trio of signals that don't quite agree with each other. The downgrade came overnight. BNP…
QFIN has shed 27% in a single week and nearly 40% over the past month, leaving it trading at $8.38 — a level that makes JP Morgan's freshly cut $9 target look optimistic in retrospect. The earnings print on August 26…
MRNA closed September at $154.27 — a stock that has tripled in six weeks, yet still sits below where most of the analysts who just raised their targets told clients to sell. The most notable development this week was…
CURA enters September with an unusual combination: a stock that has gained 10% over the past month, short sellers quietly exiting, and a 90th-percentile earnings estimate momentum reading — yet its closest peers are…
